People can go to extremes to be taken seriously and earn respect from their peers. Sometimes in doing so they do not sound very smart at all.

LinkedIn has recently posted a Skills on the Rise report showcasing the fastest-growing skills in the US. These skills can help you differentiate yourself among candidates.

Every year there are many prominent exclusivity losses in the pharmaceutical industry but this year’s list has some notable ones.

Number 1 on the list is Johnson & Johnson's Stelara, used to treat Psoriatic arthritis, plaque psoriasis,

This edition of Life Sciences Monthly Pulse from Outcome Capital is packed with in-depth analysis and strategic insights that are shaping the future of the life sciences sector. Their team of experts breaks down the key industry developments you need to know.

In what is described as an ‘always tricky’ Q4, 21 of 22 of the world’s biopharma companies that reported quarterly revenue of at least $2 billion reported an increase in revenue in Q4 of 2024. Leading those increases are Eli Lilly (+45%) and Novo Nordisk (+30%). The only company thus far reporting a decrease is Teva.

GSK’s 5-in-1 meningococcal vaccine, Penmenvy, is designed to protect people ages 10 to 25 against meningococcal serogroups A, B, C, W and Y (MenABCWY), which together cause the most persistent meningococcal disease (IMD) cases globally.

According to a recent survey of 1,824 U.S. adults in white-collar jobs by Harris Poll on behalf of global events company Freeman, 91% of Gen Z workers say they desire a balance between virtual and in-person opportunities. This will allow them to connect with others at their company and in their industry.

In 2024, Evaluate projected that the top 10 expected launches were expected to generate $15.2 billion in sales by 2028. This year’s list is projected to generate nearly double that at $29 billion in annual sales by the end of the decade. This list is the highest projected list in the last five years. One of the primary reasons for the increased figures is a new cystic fibrosis offering from Vertex Pharmaceuticals that tops the list.

Bill Gates has a “favorite book on AI” and thinks everyone should consider reading. The book is titled “The Coming Wave: Technology, Power, and the Twenty-first Century’s Greatest Dilemma” predicts artificial intelligence will change what most jobs look like, across nearly every industry, within the next five years. It is written by AI pioneer Mustafa Suleyman.

Kara Brothers, President of Starface World, likes to assess candidates’ emotional intelligence. During interviews, she relies on tough, introspective questions. She has found one of the best ways to do this is to ask the question, “In your last workplace, what really held you back?” She explains, that the goal is to uncover how adaptable and coachable someone is. Additionally, she feels a person’s self-awareness will translate well to navigating workplace challenges and collaborating with diverse personalities.

According to Emily Levine, who has been working as a recruiter for ultra-high net-worth individuals, celebrities, athletes, and musicians, these are some steps you can take to set yourself up for success in 2025.

1. Make sure your LinkedIn is up to date - First, this moment of quiet in hiring is a good opportunity to clean up your application material.

Here are 8 pro tips to get hired fast using LinkedIn from Jafar Najafov, Co-Founder & CEO of Nextool and Real Agency.

1) Complex Formatting and Graphics:
Issue: ATS may struggle to read resumes with tables, text boxes, graphics, or images.
Solution: Stick to a simple, clean layout without intricate formatting. Use standard section headings and avoid embedding information in non-text elements.

Key Points:

Macroeconomic Factors: Lowering interest rates and the election cycle are impacting the life sciences market in similar ways to broader market trends.

Daniel Haarburger, CEO of Woof, says he always asks job candidates a straightforward, everyday interview question: What does your day-to-day life look like?

He recently shared that one candidate gave him a textbook example of the “worst response that I’ve ever heard.” He said: “Life’s a hot-mess express right now. It’s pretty wild.”

Aucatzyl, a therapy to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia has received FDA approval. Aucatzyl joins Gilead’s Tecartus and Novartis’ Kymriah. Autolus has wrapped up all pre-launch activities and will now move to finish the final steps involved in onboarding treatment centers.

Johnson & Johnson and Legend Biotech’s Carvykti showed it could prevent disease progression in the earlier treatment of multiple myeloma, now results are showing that a single dose slashed the death risk by 45% compared with two traditional combination treatments in myeloma patients who had received at least one prior line of therapy, according to an update of the phase 3 CARTITUDE-4 trial.

Paiji Yoo, CEO and co-founder of Blueland says, “I like to lead as an open and collaborative leader. And I think that is a must-have for every team member that we bring on.”

The FDA has cleared Apple's new sleep apnea detection feature for use. It will be available on Apple Watch Series 9, Series 10 and Ultra 2 later this month.

FiercePharma is shining a spotlight on the people and companies who are driving meaningful change in healthcare, pharma and biotech. This is the second edition of the Fierce 50, and honors a steadfast dedication and the vision that push these industries forward.

Chances are you have heard this question during an interview, “Tell me about yourself.” While most interviewers use this as an opener to an interview, answering it with a breakdown of your whole history could be a mistake. Think about using this time to make a strong first impression.

With the approval of Livdelzi, Gilead Sciences is growing its liver disease portfolio. Livdelzi is used to treat primary biliary cholangitis (PBC), a rare liver disease that occurs when your body’s immune system incorrectly attacks your bile ducts.

We know many of you are struggling with being downsized and others are frustrated with the interview process and lack of feedback from companies. A friend shared this inspiring article and we are passing it on. Times will change, they always do!

The FDA has approved Ascendis’ Yorvipath, a hormone replacement therapy to treat hypoparathyroidism. Ascendis was ready to bring the drug to the market 15 months ago but was rejected due to a manufacturing problem. Then 3 months ago things were delayed when the FDA said they needed additional time to make its decision. Initial supplies should be available in the first quarter of 2025.

A 2022 recall stopped the launch of Roche's eye implant, Susvimo, due to manufacturing concerns. This is good news for patients with wet age-related macular degeneration (AMD) as Susvimo is a refillable eye implant that only requires two refills per year offering an alternative to standard-of-care eye injections to treat the disease.

It’s always important to have some questions prepared for your interview. According to Andrew McCaskill, a LinkedIn career expert, there is one question you should always ask.